Neurocrine Current Deferred Revenue from 2010 to 2024

NBIX Stock  USD 134.97  1.90  1.43%   
Neurocrine Biosciences Current Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Current Deferred Revenue is likely to outpace its year average in 2024. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2001-03-31
Previous Quarter
339.9 M
Current Value
24.8 M
Quarterly Volatility
92.1 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 22.4 M, Interest Expense of 7.4 M or Selling General Administrative of 894.2 M, as well as many indicators such as Price To Sales Ratio of 6.48, Dividend Yield of 0.0 or PTB Ratio of 6.13. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.
  
Check out the analysis of Neurocrine Biosciences Correlation against competitors.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Latest Neurocrine Biosciences' Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of Neurocrine Biosciences over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Neurocrine Biosciences' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Slightly volatile
   Current Deferred Revenue   
       Timeline  

Neurocrine Current Deferred Revenue Regression Statistics

Arithmetic Mean78,344,750
Coefficient Of Variation201.61
Mean Deviation120,824,000
Median10,231,000
Standard Deviation157,950,368
Sample Variance24948.3T
Range456.6M
R-Value0.64
Mean Square Error15753.4T
R-Squared0.41
Significance0.01
Slope22,715,838
Total Sum of Squares349276.5T

Neurocrine Current Deferred Revenue History

2024410.4 M
2023390.9 M
2022339.9 M
2021-16.5 M
2020-10.3 M
2019-46.2 M

About Neurocrine Biosciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Neurocrine Biosciences income statement, its balance sheet, and the statement of cash flows. Neurocrine Biosciences investors use historical funamental indicators, such as Neurocrine Biosciences's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Neurocrine Biosciences investors may use each financial statement separately, they are all related. The changes in Neurocrine Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Neurocrine Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Neurocrine Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue390.9 M410.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.